A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

Status:	Archived
Conditions:	Depression, Major Depression Disorder (MDD)
Therapuetic Areas:	Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:	No
Age Range:	Any
Updated:	7/1/2011
Start Date:	February 2011
End Date:	March 2012

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy

The purpose of this study is to assess the safety and effect of TC-5214 as a single therapy
in patients with major depressive disorder who exhibit inadequate response to
antidepressants.

We found this trial at

sites

Clinical Trial Facility in Bellingham Washington

Bellingham, Washington

from

Bellingham, WA